Articles tagged with Heart Failure
Researchers at UT Southwestern Medical Center report that pioglitazone and rosiglitazone can cause or exacerbate heart failure and pulmonary edema in certain patients, highlighting the need for cautious prescribing practices.
The CHARM Programme demonstrates clear benefits of Atacand in treating heart failure, reducing risk by 23% in ACE-inhibitor intolerant patients and 15% in those taking conventional therapy. Additionally, Atacand shows a trend towards reduced cardiovascular death and hospitalizations in patients with preserved left ventricular function.
A new study aims to investigate how physicians treat end-stage heart failure patients, focusing on the use of inotropic drugs. The research hopes to provide a framework for selecting care options, including palliation, for older heart failure patients near the end of life.
Researchers found that 13.5% of patients with heart failure were prescribed metformin or thiazolidinediones in 1998-99, increasing to 24.4% by 2000-01. These medications are recommended against for patients with significant heart failure symptoms due to potential side effects.
A study published in The Lancet found that carvedilol significantly reduces mortality and improves average life-expectancy by eight years compared to metoprolol. Additionally, carvedilol shows promise in improving ventricular function for patients with heart failure due to coronary artery disease.
A recent study found that heart failure patients cared for by cardiologists had significantly lower one-year death rates compared to those treated by other types of physicians. The study analyzed data from 38,702 Canadian patients and found that cardiologist-managed patients had a mortality rate of 28.5%, compared to 31.7% for general ...
Researchers developed a guideline to identify low-risk heart failure patients for targeted home treatment, reducing unnecessary hospital stays. The study used data from over 33,000 cases and identified nearly 16% of patients as low risk, promising success in similar contexts.
Researchers found that patients with combined devices showed significant improvements in quality of life, physical functioning, and exercise capacity compared to those without the devices. The study's findings have implications for treating heart failure, a disease with a five-year mortality rate of 50 percent after diagnosis.
Researchers highlight importance of controlling blood pressure and vascular risks in heart failure management. They propose a new classification system for heart failure stages, emphasizing the need for early intervention.
A large-scale prospective trial will determine whether exercise can reduce mortality for patients with heart failure or any other disease. The study, led by Duke University, aims to find out if exercise has an effect on reducing hospitalizations among heart failure patients.
Researchers at Johns Hopkins discovered a compound that doubles the hearts' ability to contract and relax, stimulating the release of calcitonin gene-related peptide. This improvement is particularly notable in failing hearts, without any reported toxicity.
A new international study found that the life-saving effect of eplerenone began soon after patients started taking the drug following their heart attacks. The study showed a significant reduction in deaths and hospitalizations among heart attack patients with heart failure, especially when combined with other heart medications.
Researchers at Emory University have developed an innovative technique for biventricular resynchronization that minimizes risks and eliminates ionizing radiation. The new approach uses tiny incisions and specialized tools to connect leads to the heart, offering a safer and more efficient alternative to traditional methods.
A gene mutation that improves heart failure in mice is fatal in humans, highlighting the need for human-specific studies. Researchers found that inhibiting PLN gene in mice restored impaired calcium signaling and muscle contraction, but led to lethal heart failure in humans.
A team of researchers has identified a genetic mutation in phospholamban that disrupts calcium regulation in the heart, leading to dilated cardiomyopathy and heart failure. The discovery provides new insights into the mechanisms underlying heart failure and holds promise for future treatments.
Researchers found a mutant protein, phospholamban (PLN), that disrupts calcium signaling in heart muscle cells, leading to contractile dysfunction and heart failure. The study provides insight into the fundamental signals that tip a diseased heart into failure.
Researchers have pinpointed a genetic defect in the phospholamban protein as the cause of inherited dilated cardiomyopathy. The discovery may lead to targeted treatment for this disorder, which affects 4.7 million Americans and costs $17.8 billion annually.
A meta-analysis of randomized clinical trials found that pacemaker therapy reduced death from progressive heart failure by 51% and hospitalizations by 29%. The device range in cost $20,000 to $50,000 and improves quality of life for heart failure patients.
A genetic defect in muscle growth and survival is linked to human heart failure, causing the heart muscle to lose its ability to adapt to stress. Researchers identified a specific gene mutation that disrupts normal stretch activity, leading to enlarged hearts with thin ventricular walls.
A six-year study of 100 heart failure patients who received the HeartMate device at Michigan Medicine found excellent one-year survival rates and improved hospital stays. Eighty-two percent of patients were able to go home, and problems with the device have decreased as doctors gain experience.
A landmark study found that left-ventricular assist devices (LVADs) for heart failure patients cost $196,699, similar to liver transplantation ($250,000). The device has been shown to significantly improve survival and quality of life. Improving management of these critically ill patients could reduce costs.
Starting beta-blocker before discharge in heart failure patients significantly improves usage, reducing death and morbidity by over 35%. Early hospital-initiated therapy boosts 91% 60-day medication adherence rate.
Researchers found that patients with diastolic heart failure have severely reduced exercise capacity and quality of life, similar to those with classic congestive heart failure. The study supports the existence of a second type of heart failure, highlighting the need for intensive research and treatment development.
A new study by Wake Forest University School of Medicine has confirmed the existence of diastolic heart failure, a condition that affects older adults' quality of life and exercise capacity. People with this condition experience severely reduced physical ability and increased neuroendocrine activity.
A recent study from the Framingham Heart Study has shown a small but significant improvement in heart-failure survival rates since the 1990s. This increase is attributed to the widespread adoption of proven-effective medications such as beta-blockers, ACE inhibitors, and aldosterone antagonists. The findings suggest that treating patie...
A new NHLBI study has found improved heart failure survival rates, with deaths decreasing by 12% per decade for both men and women. The study, which analyzed data from 10,317 participants over 50 years, also revealed a significant drop in new cases of heart failure among women during the same period.
A large study of older adults with heart failure found that those with diastolic heart failure had significantly higher mortality rates than those with systolic heart failure. Diastolic heart failure, which affects the heart's main chamber filling with blood, has a much higher prevalence among elderly patients and is responsible for mo...
Researchers are exploring a new stem cell therapy, called therapeutic angiogenesis, to grow new blood vessels in damaged heart muscle. The treatment, which uses cord blood stem cells, aims to improve outcomes for people with severe coronary artery disease and congestive heart failure.
Researchers found that genes, rather than blood pressure or age, significantly impact heart function and the risk of developing diastolic heart failure. The study suggests that an individual's genetic makeup may be programmed from birth, determining their future heart health.
Researchers found a genetic link between a specific enzyme and increased risk of heart failure in alcoholics, with those having two copies of the D allele facing a 16 times greater risk. This discovery opens up possibilities for uncovering other genetic predispositions for various alcohol-related diseases.
The study of over 5,000 participants found a significant association between excess weight and increased risk of heart failure in both men and women. Obesity was independently linked to an increased risk of heart failure, even after accounting for other risk factors.
Researchers found omapatrilat to be effective in treating heart failure, with some indications of superiority over standard ACE inhibitors. Patients with both hypertension and heart failure showed the greatest benefit from omapatrilat.
A retrospective analysis of 4,054 study participants found that enalapril, an ACE inhibitor commonly given to patients with heart failure, is effective in both black and white populations. Despite equal response rates, black patients still had increased rates of progression to heart failure.
A new study published in the New England Journal of Medicine shows that cardiac resynchronisation therapy systems improved NYHA functional class, six-minute walk distance, and quality of life for patients with moderate-to-severe heart failure. The treatment also reduced hospitalisations by 50% and hospital days by 77%.
A University of North Carolina at Chapel Hill study found that nearly one in four metformin prescriptions were given to patients with contraindications. The study suggests that providers may not be adequately documenting the risks of lactic acidosis and should consider counseling patients on metformin use.
A new study suggests that smaller aneurysms are often safer left untreated, with potential benefits including reduced risk of complications and cost savings. The research found nearly 98% survival rate among patients undergoing AAA surgery at participating VA hospitals.
Researchers found that elevated troponin I levels may predict future heart failure in cancer patients, even if the heart appears to be functioning normally. ACE inhibitors have shown promise in restoring cardiac function and preventing cardiotoxicity in breast cancer patients treated with anthracyclines.
Chronic heart failure affects 5 million US people, with poor hospital outcomes and high readmission rates. Researchers conducted large placebo-controlled trials to develop treatment guidelines for this condition.
A new blood test, Triage BNP Test, has been shown to accurately diagnose congestive heart failure (CHF) with a high accuracy rate of nearly 90% in a multinational trial. The test detects elevated levels of the hormone B-type natriuretic peptide (BNP), which signals a failing heart.
Researchers at Massachusetts General Hospital have developed a gene therapy approach that inhibits phospholamban, a protein blocking normal calcium flow in the heart. This treatment strategy has shown promise in improving contraction and relaxation in diseased cells.
Researchers at Jefferson Medical College and University of Barcelona found that moderate drinking from one to four drinks a day improved heart function in men with alcohol-related heart failure. The study suggests a threshold drinking level for alcohol-related heart damage, below which there is no harm.
A large study of men's health habits found that a prudent diet significantly reduces the risk of developing type 2 diabetes. The study indicates that avoiding weight gain and eating a balanced diet may substantially reduce this risk, highlighting the importance of a healthy lifestyle in preventing the disease.
Researchers tested BNP levels in 325 patients with dyspnea, finding those with high levels had a 51% chance of developing congestive heart failure or dying within six months. The study supports the use of BNP testing as a tool for diagnosing patients at risk of congestive heart failure.
Elderly women with depression are nearly twice as likely to develop heart failure over a 14-year period. Depression also increases the risk of physical illnesses like hypertension and diabetes that contribute to heart disease.
Researchers will study the effects of aging on the heart and evaluate an endurance exercise-training program's ability to improve diastolic function and serve as a therapy for congestive heart failure. The study aims to identify the precise dose of exercise necessary to restore normal diastolic function.
UCSD researchers identified a gene, KChIP2, that regulates critical electrical currents in the human heart and is associated with increased vulnerability to arrhythmias. The study found that a defective version of this gene can lead to malignant heart rhythms and sudden death in patients with heart failure.
Researchers at Columbia University have discovered a treatment for heart failure by correcting a specific cellular defect. Beta blockers prevent the excessive phosphorylation of the ryanodine receptor, allowing it to respond to signals and release calcium ions as needed. This finding offers new hope for treating heart failure.
A recent study found a significant association between low systolic blood pressure levels (below 130) and cognitive impairment in older patients with heart failure. The researchers suggest that routine management of heart failure should include assessment of cognitive performance to detect early signs of cognitive dysfunction.
Valsartan has been shown to improve symptoms and outcomes in patients with heart failure, reducing morbidity by 13.2% and hospitalizations by 27.5%. The study also found significant improvements in quality of life and ejection fraction.
A landmark clinical trial at 22 medical centers has found that implanted heart pumps with wearable controls significantly increase the likelihood of terminally ill heart failure patients surviving a year, with a 52.1% one-year survival rate compared to 24.7% for those receiving medication and medical monitoring.
Acupuncture was found to significantly reduce sympathetic nerve activity in critically ill chronic heart failure patients, but blood pressure and heart rate remained unaffected. Further study is needed to confirm the treatment's effectiveness and potential benefits for patients with severe heart failure.
The Val-HeFT study found that valsartan significantly reduced total heart failure hospitalizations and morbidity, with a 27.5% delay to first hospitalization. Valsartan also attenuated the increase in norepinephrine levels associated with heart failure.
Research studied deaths of 508 patients with terminal heart failure, finding that men were most likely to die near dawn, while women were at highest risk in the early morning. The study suggests hormonal patterns and daily biological ebb and flow may contribute to these findings.
Researchers at Johns Hopkins Medicine found that allopurinol, a medication commonly used to treat gout, can improve heart muscle efficiency and reduce energy consumption in patients with congestive heart failure. The study showed a 20% reduction in energy consumption without affecting contraction strength.
Men with stable chronic heart failure experienced improved sexual activity and quality of life after regular cycling. The study found significant improvements in endothelial function, measured through brachial artery dilation and oxygen uptake, resulting from the exercise routine.
A new study funded by the NHLBI shows that a type of implantable heart pump can extend and improve the lives of terminally ill patients with end stage heart failure. The HeartMate LVAD was shown to have a 52% one-year survival rate, compared to 25% for those receiving standard medical management.
A survey of practice nurses found that 85% are underestimating the prevalence of insulin resistance in type 2 diabetes patients. This lack of awareness can lead to inadequate treatment and education, highlighting the need for increased understanding of insulin resistance as a fundamental cause of type 2 diabetes.
A survey found that nearly two-thirds of GPs are unaware that insulin resistance is present in 92% of people with type 2 diabetes. This lack of understanding can lead to suboptimal treatment, as insulin resistance improves glycaemic control and reduces cardiovascular complications.
Researchers at Rush-Presbyterian-St. Luke's Medical Center are testing two forms of behavior management to help patients with chronic heart failure manage their illness. The 18-week course and weekly tip sheets aim to teach patients how to monitor their reactions to stressful events and make lifestyle changes.
A new study by Yale University aims to investigate the effectiveness of a tailored home-based exercise regimen on quality of life and functional capacity in heart failure patients. The research also seeks to assess the program's financial practicality and potential cost savings compared to traditional care.